The comparison people actually face is rarely between two drugs. It is between a drug they pay for monthly and an operation they pay for once, and a claims analysis of 6,748 patients with a BMI of 35 or higher and type 2 diabetes put numbers on both sides [1]. The break-even arithmetic this desk has run before is in how long the drug takes to cost more than surgery, and this study measures the same question from insurance records rather than list prices.
Over three years, semaglutide carried the highest out-of-pocket cost at $7,752, against $5,980 for sleeve gastrectomy and $6,591 for gastric bypass. Total spending, counting what the insurer paid as well, was not statistically different across the three groups. Those two sentences together are the finding: the choice barely moved what the system spent, and moved a good deal of it onto the patient.
On outcomes the surgical arms did better in places. Compared with semaglutide, sleeve gastrectomy was associated with fewer long-term admissions (HR 0.79, 95% CI 0.72–0.86) and fewer major adverse cardiovascular events (HR 0.79, 95% CI 0.66–0.93). Gastric bypass also showed fewer such events (HR 0.71, 95% CI 0.59–0.88) while showing more emergency visits (HR 1.36) and more inpatient admissions (HR 1.25), which is roughly what a bigger operation with a longer recovery would predict.
Read those outcome numbers with the population in mind. The surgical patients started with higher BMI and more comorbidities, so they were sicker, and confounding of that shape usually flatters the drug rather than the operation. The authors adjust with inverse probability weighting, generalized linear models and instrumental variables, which narrows the problem without removing it, and none of it makes this a randomized comparison.
For someone deciding today, the useful translation is that the monthly figure is not the whole cost of either path, and a drug bought for three years is a commitment closer in size to an operation than the monthly price suggests. What the drug is worth against what it prevents is worked through in is a GLP-1 worth what it costs, the case for taking one first is in before bariatric surgery, and the case for taking one afterwards, when an operation has underdelivered, is in after surgery falls short.